PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
13 Nov 2023
PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD)
This drug candidate has
demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD
[2]
PKD is a life-changing disease affecting 1 in every 1,000 people[3]
Half of the patient population with PKD will require a kidney transplant by the age of 60 due to the absence of impactful treatment options in this disease[4]
PKD represents an addressable market of
>US$10 billion p.a. and is an area of major commercial interest for the drug development industry[5]
Pre-clinical models suggest that addressing the underlying cause of PKD (the way that PYC's drug candidate works) could
arrest the course of the disease in humans, enabling damaged kidneys to
regenerate and
restore function[6]
PYC plans to accelerate this drug candidate into human trials in ~12 months – pursuing a potential high-velocity path through clinical trials to market[7]
Investor Webinar Friday 17 November
PYC will host an investor call at 9am AWST/12pm AEDST on Friday 17 November to discuss these results – investors can register for the call here:
https://us02web.zoom.us/webinar/register/WN_p2QQKKZ-TxOms2MOaUjijg
PERTH, Australia and SAN FRANCISCO, Nov. 13, 2023 /PRNewswire/ -- PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8].
Continue Reading
Preview
Source: PRNewswire
Figure 1
Preview
Source: PRNewswire
Figure 2
Preview
Source: PRNewswire
Figure 3
Preview
Source: PRNewswire
Figure 4
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.